



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Thomas M. DiMauro, Mohamed Attawia, Hassan Serhan, Martin A. Reynolds, Melissa Grace, Sudhakar Kadiyala, David Urbahns, Scott Bruder, Gregory Collins, Laura J. Brown, Jeffrey Geesin, Pamela L. Plouhar, Catherine W. Smith and John Siekierka

Application No.: 10/630,227

Group: 1647

Filed: July 30, 2003

Examiner: Betty L. Lee

Confirmation No.: 8291

For: TRANS-CAPSULAR ADMINISTRATION OF HIGH SPECIFICITY
CYTOKINE INHIBITORS INTO ORTHOPEDIC JOINTS

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
10-11-05	<i>Jennifer Torpey</i>
Date	Signature
Jennifer Torpey	
Typed or printed name of person signing certificate	

REPLY TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Responsive to the Restriction Requirement dated August 9, 2005, the claims of Group I (Claims 1-65), drawn to a method of treating an inflamed orthopedic joint, are elected for prosecution. Applicant reserves the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicant does not hereby abandon or waive any rights in the non-elected inventions.

An extension of time to respond to the Restriction Requirement is respectfully requested. A Petition for an Extension of Time and the appropriate fee are being filed concurrently.

Species Elections

High Specificity Antagonist

Responsive to the requirement for an election of species for searching purposes, Applicant hereby elects inhibitor of TNF- α synthesis. Claims readable on this elected species are Claims 1-4, 14, 30 and 34-65.

Types of Joint

Responsive to the requirement for an election of species for searching purposes, Applicant hereby elects the knee joint. Claims readable on the elected species are Claims 1, 2, 5-29 and 31-65.

Interleukin

Interleukin has not been elected as the species of high specificity antagonist. Therefore, no species of interleukin will be elected.

P38 Kinase Inhibitor

p38 kinase inhibitor has not been elected as the species of high specificity antagonist. Therefore, no species of p38 kinase inhibitor will be elected.

Heterocycle

Heterocycle has not been elected as the species of high specificity antagonist. Therefore, no species of heterocycle will be elected.

Anti-proliferative Agent

Anti-proliferative agent has not been elected as the species of high specificity antagonist. Therefore, no species of anti-proliferative agent will be elected.

Apoptosis Inhibitor

Apoptosis inhibitor has not been elected as the species of high specificity antagonist. Therefore, no species of apoptosis inhibitor will be elected.

NO Synthase

NO synthase has not been elected as the species of high specificity antagonist. Therefore, no species of NO synthase will be elected.

Additional Agent

Responsive to the requirement for an election of species for searching purposes, Applicant hereby elects growth factor. Claims readable on this elected species are Claims 1-34, 36-51 and 53-65.

Please note that Claims 1-2, 14, 34, 36-51 and 53-65 are readable on all three elected species.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders
Deirdre E. Sanders
Registration No. 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: October 11, 2005